Cerevel Therapeutics (CERE) PT Upped to $33 on CVL-231 Data, a Best Case Scenario - Stifel
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $33.00 price target on Cerevel Therapeutics (NASDAQ: CERE) on positive CVL-231 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
